Skip Navigation

DRUG RECORD

 

TRIMIPRAMINE

OVERVIEW
Trimipramine

 

Introduction

Trimipramine is a tricyclic antidepressant used in the therapy of major (endogenous) as well as reactive (exogenous) depression.  In clinical trials, trimipramine therapy was not associated with an increased rate of elevations in serum aminotransferase levels, and it has yet to be linked to instances of clinically apparent acute liver injury.

 

Background

Trimipramine (trye mip' ra meen) is a tricyclic antidepressant that is believed to act by enhancing serotonergic and dopaminergic neurotransmission.  Like most tricyclic antidepressants, trimipramine is a weak inhibitor of serotonin, norepinephrine and dopamine reuptake, but also has direct antagonist activity for some serotonin and adrenergic receptors.  Trimipramine has been shown to alleviate symptoms of depression, both in patients with neurotic or situation depression as well as those with major, endogenous depression.  Trimipramine was approved for use in the United States in 1979 and is still clinically available, although now not widely used.  Trimipramine is available as capsules of 25, 50 and 100 mg generically and under the brand name Surmontil.  The typical initial dosage in adults is 75 mg daily in divided doses, which can be modified to once daily and increased in total dose based upon efficacy and tolerance to as highly as 150 to 200 mg once daily.  Common side effects are diarrhea, nausea, vomiting, fatigue, drowsiness, headache, insomnia, weight gain and sexual dysfunction.  Rare potential side effects include increased suicide risk, cardiac arrhythmias, urinary retention and acute serotonin syndrome.

 

Hepatotoxicity

In clinical trials, liver test abnormalities were uncommon in patients taking trimipramine (<1%) and generally no more frequent than in placebo or comparator arm recipients.  No instances of acute, clinically apparent liver injury attributed to trimipramine have been reported.  Most other tricyclic antidepressants in clinical use have been associated with occasional instances of acute liver injury, usually arising within 2 to 8 weeks of starting therapy.  The pattern of serum enzyme elevations varied from hepatocellular to cholestatic and autoimmune features are uncommon.  Immunoallergic features (rash, fever, eosinophilia) can occur, but are not prominent.  Most cases of acute liver injury due to tricyclic antidepressants are mild-to-moderate in severity and resolve within one to three months.  Acute liver failure due to tricyclic antidepressants has been described, but is very rare.  No such cases have been linked to trimipramine use.

 

Mechanism of Injury

The mechanism by which trimipramine might cause liver injury is not known.  Trimipramine is metabolized at least in part by the liver, but it has not been linked to significant drug-drug interactions.

 

Outcome and Management

The serum aminotransferase elevations that occur on amoxapine therapy are usually self-limited and do not require dose modification or discontinuation of therapy.  No instances of acute liver failure or vanishing bile duct syndrome due to amoxapine have been reported.  There is no information on cross sensitivity to liver injury between amoxapine and other tricyclic antidepressants, but switching to another class of agents (such as the selective serotonin reuptake inhibitors) is probably prudent.

 

Drug Class:  Antidepressant Agents

 

Other Drugs in the Subclass, Tricyclics:  Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline, Protriptyline

 

Top of page


PRODUCT INFORMATION
Trimipramine

 

REPRESENTATIVE TRADE NAMES
Trimipramine – Generic, Surmontil®

 

DRUG CLASS
Antidepressant Agents

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NO. MOLECULAR FORMULA STRUCTURE
Trimipramine 739-71-9 C20-H26-N2 Trimipramine chemical structure

Top of page


REFERENCES
Trimipramine

 

References updated: 08 June 2015

  1. Zimmerman HJ. Antidepressants. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 493-8.  (Expert review of hepatotoxicity published in 1999, trimipramine is listed as a tricyclic antidepressant with a very low incidence of hepatotoxicity).

  2. Larrey D. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 2nd ed. New York: Informa Healthcare USA, 2007, pp. 443-62.  (Review of hepatotoxicity published in 2007; mentions that trimipramine, like other imipramine antidepressants, has been implicated in rare cases of acute hepatitis).

  3. O'Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman.s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 397-416.  (Textbook of pharmacology and therapeutics).

  4. Salzmann MM. A controlled trial with trimipramine, a new anti-depressant drug. Br J Psychiatry 1965; 111: 1105-6. PubMed Citation  (Among 27 depressed patients treated with either imipramine or trimipramine for an unstated duration, response rates were better with trimipramine; no description of side effects was provided).

  5. Burke BV, Sainsbury MJ, Mezo BA. A comparative trial of amitriptyline and trimipramine in the treatment of depression. Med J Aust 1967; 1: 1216-8. PubMed Citation  (Among 26 patients with severe depression treated with either amitriptyline or trimipramine for 4 weeks, only 19 could complete the study and efficacy and side effects were similar with the two agents; no mention of ALT elevations or hepatotoxicity).

  6. Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 1979; 2 (6201): 1315-7. PubMed Citation  (Among 135 patients with depression treated with trimipramine, an MAO inhibitor or both for 6 weeks, trimipramine alone was more effective than the combination or the MAO inhibitor alone; side effects were not specifically addressed and no mention of ALT elevations or hepatotoxicity).

  7. Settle EC Jr, Ayd FJ Jr. Trimipramine: twenty years' worldwide clinical experience. J Clin Psychiatry 1980; 41: 266-74. PubMed Citation  (Review of the 20 year clinical experience with trimipramine [largely in Europe] before its approval in the US in 1979 mentions that side effects are similar to those with other tricyclics, the most common being sedation, dry mouth, tremor, headaches and, more rarely, excitation and agitation; no mention of ALT elevations or hepatotoxicity).

  8. Rifkin A, Saraf K, Kane J, Ross D, Klein DF. A comparison of trimipramine and imipramine: a controlled study. J Clin Psychiatry 1980; 41: 124-9. PubMed Citation  (Among 38 hospitalized patients with depression treated with trimipramine or imipramine for 3 weeks, clinical efficacy was similar, but side effects were less with trimipramine; no mention of ALT elevations or hepatotoxicity; 10 patients did not complete the study due to "uncooperativeness", clinical deterioration or adverse reactions).

  9. Assalian P, Rosengarten MD, Phillips R. A comparative trial of the antidepressant, anxiolytic, and cardiovascular effects of trimipramine and doxepin in depressed hospitalized patients. J Clin Psychiatry 1985; 46: 90-4. PubMed Citation  (Among 25 hospitalized patients with depression treated with trimipramine or doxepin for 4 weeks, results of monitoring of laboratory tests were not provided).

  10. Cournoyer G, de Montigny C, Ouellette J, Langlois R, Elie R, Caille G, le Morvan P. A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol 1987; 7: 385-93. PubMed Citation  (Among 34 patients with major depression treated with trimipramine or amitriptyline for 21 days, routine laboratory test results did not change in either group).

  11. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J(Clin Res Ed) 1987; 295 (6605): 1021-4. PubMed Citation  (Analysis of prescription rates and overdose fatality reports in the UK between 1975 and 1984 found the highest fatal toxicity indices for tricyclic antidepressants [38 deaths per million] compared to MAO inhibitors [27], with high rates of amitriptyline [46], nortriptyline [39], imipramine [28] and trimipramine [28]).

  12. Lapierre YD. A review of trimipramine. 30 years of clinical use. Drugs 1989; 38 Suppl 1:17-24. PubMed Citation  (Summary of more than 25 trials of trimipramine in comparison to placebo and other antidepressants found the side effect profile similar to other tricyclic antidepressants; no mention of ALT elevations or hepatotoxicity).

  13. Bender S, Olbrich HM, Fischer W, Hornstein C, Schoene W, Falkai P, Haarmann C, et al.; Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. Pharmacopsychiatry 2003; 36: 61-9. PubMed Citation  (Among 95 patients with acute schizophrenia treated with trimipramine or perazine for 36 days, the antipsychotic effect of the phenothiazine was greater; no mention of changes in ALT levels or hepatotoxicity).

  14. Wehmeier PM, Kluge M, Maras A, Riemann D, Berger M, Kohnen R, Dittmann RW, et al. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. Pharmacopsychiatry 2005; 38: 13-6. PubMed Citation  (Among 41 elderly patients with major depression treated with trimipramine or fluoxetine for 6 weeks, both efficacy and side effects were similar; one patient on trimipramine developed abnormal ALT levels, but specifics and outcome were not provided).

  15. Gutscher K, Rauber-Lü, Haller M, Braun M, Kupferschmidt H, Kullak-Ublick GA, Ceschi A. Patterns of toxicity and factors influencing severity in acute adult trimipramine poisoning. Br J Clin Pharmacol 2013; 75: 227-35. PubMed Citation  (Over an 18 year period, 230 cases of suspected trimipramine overdose were reported to a Swiss Toxicology Registry, mostly due to suicide attempt, symptoms being somnolence [61%], tachycardia [19%], coma [18%] and convulsions [6%], with fatal outcome in 3 patients [8.4-25 g doses] caused by cardiovascular collapse; no mention of liver manifestations or hepatic failure).

  16. Lucena M, Carvajal A, Andrade R, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf 2003; 2: 249-62. PubMed Citation  (Review of hepatotoxicity of antidepressants; antidepressant use has increased markedly between 1992 and 2002, accounting for 5% of cases of hepatotoxicity; SSRIs are less likely to cause injury than tricyclics and MAO inhibitors; trimipramine is not mentioned).

  17. Degner D, Grohmann R, Kropp S, RüE, Bender S, Engel RR, Schmidt LG. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 Suppl 1: S39-45. PubMed Citation  (Analysis of adverse drug reactions reported from 1993-2000 in 35 psychiatric hospitals; 0.3% of trimipramine recipients had a severe adverse event which was hepatic in approximately one-third, these rates being similar to the overall rates of tricyclics).

  18. DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother 2007; 41: 1201-11. PubMed Citation  (Review of drug induced liver injury and reports of injury from MAO inhibitors, SSRIs, tricyclics and atypical agents; no specific discussion of trimipramine).

  19. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76. PubMed Citation  (Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, including 4 from psychotropic agents [quetiapine, nefazodone, fluoxetine, venlafaxine], but none were linked to tricyclic antidepressants).

  20. Park SH, Ishino R. Liver injury associated with antidepressants. Curr Drug Saf 2013; 8: 207-23. PubMed Citation  (Review of drug induced liver injury due to antidepressants including SSRIs; trimipramine is not discussed).

  21. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25. PubMed Citation  (In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, one being attributed to an SSRI [venlafaxine], but none to a tricyclic antidepressant).

  22. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014; 171: 404-15. PubMed Citation  (Review of the frequency and clinical features of drug induced liver injury due to antidepressants; imipramine, desipramine and amitriptyline are discussed, but not trimipramine).

  23. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. PubMed Citation  (Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 20 cases were attributed to antidepressants, only one of which was a tricyclic [imipramine]; none were linked to trimipramine).

Top of page